Additional Information

Description

Insulin Lispro is a rapid-acting human insulin analog designed to manage blood glucose levels in individuals with diabetes mellitus. It has a fast onset of action, typically beginning within 15 minutes after subcutaneous administration. This insulin analog mimics physiological insulin release, facilitating glucose uptake by muscle and fat cells while inhibiting hepatic glucose production. It is suitable for use in both type 1 and type 2 diabetes and can be administered via injection or an insulin pump.

Each milliliter of Insulin Lispro contains 100 units (U-100), providing a concentrated formulation for glycemic control. The 10 mL vial allows multiple-dose administration, ensuring flexibility in dosing regimens. The formulation includes zinc and other stabilizers to maintain insulin activity. Insulin Lispro should be injected within 15 minutes before or immediately after meals to effectively manage postprandial blood sugar spikes.

Due to its rapid onset and shorter duration of action compared to regular insulin, Insulin Lispro reduces the risk of delayed hypoglycemia. Close monitoring is necessary to prevent acute hypoglycemic episodes. Patients using Insulin Lispro should regularly check blood glucose levels and adjust doses based on dietary intake, activity level, and physician recommendations.